PR View by Melissa Hill

Share this article:
When it comes to life science companies, change can happen overnight. Each morning we wake up to a flurry of headlines affecting the industry, including product failures and setbacks, proposed legislation impacting product exclusivity and new scientific discoveries. While these might be ordinary headlines to most of us, for employees and shareholders involved in these companies, these news events can mean significant change.

With change comes an opportunity for communication and a need for information. As the life science industry matures and companies grow, this presents an even greater challenge in communicating effectively with all key stakeholders. Companies that were once a small group of employees sitting around the boardroom are blossoming into organizations with numerous departments and locations. 

Keeping these employees aware of the company's mission, milestones, achievements and setbacks becomes critical with growth. As life science companies experience change with growth, it provides an ideal time to assess internal and external perceptions. Are employees aware of the company's vision? Are they aware of how the company positions itself to its shareholders? Do they know the plan for the upcoming product approval and launch? 

And equally as important, do external perceptions match internal perceptions? Do shareholders and customers know the direction of the company? Do shareholders know the timeline for your product launch? Make these questions a regular part of your communications plan. Don't be afraid to ask these questions; you might be surprised by what you hear.

As the tide shifts for life science companies, the famous words “knowledge is power” ring true for all of our key stakeholders.

Melissa Hill is VP at Porter Novelli Life Sciences

Share this article:

Email Newsletters

More in News

BI rethinks hepatitis business, posts 2013 results

BI rethinks hepatitis business, posts 2013 results

Boehringer Ingelheim says it is no longer pursuing an interferon-free combination of faldaprevir and deleobuvir.

Roche wraps quarter with two fewer pipeline medications

Roche wraps quarter with two fewer pipeline medications

Roche also announced first-quarter sales shrank 1%.

2013 favored specialists, specialty Rx

2013 favored specialists, specialty Rx

The latest IMS Institute for Healthcare Informatics assessment of 2013's prescription drug use shows that 2.3% of prescriptions account for 30% of a patient's out-of-pocket prescription costs.